Bioqube Ventures is pleased to welcome CatalYm GmbH to its portfolio, co-leading a $150M financing with Canaan alongside new investors Omega Funds, Forbion and Gilde Healthcare and with the support of existing investors.
Bioqube Ventures
Venture Capital and Private Equity Principals
“The greatest investment we can ever make is to invest our life in the life of someone else.”
About us
Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Bioqube Ventures was incorporated by Debora Dumont and Nico Vandervelpen in 2015 with the sole aim to invest in groundbreaking and innovative therapeutics. In 2016, Bioqube launched its first investment vehicle on the Janssen campus in Beerse. In 2020, Bioqube launched its second investment vehicle "Bioqube Factory Fund I - BFF I" … An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients. … A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. BFF I is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (“EFSI”) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing.
- Website
-
http://www.bioqubeventures.com
External link for Bioqube Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Brussels
- Type
- Privately Held
- Founded
- 2015
Locations
-
Primary
Get directions
Brussels, BE
Employees at Bioqube Ventures
Updates
-
We are pleased to announce the launch of Commit Biologics. A testament to our venture build strategy co-powered by Novo Holdings. #biotech #investment
-
-
Bioqube Ventures reposted this
Bioqube Ventures is pleased to welcome SynOx Therapeutics to its portfolio, co-leading a $75M Series B alongside existing investors Forbion and HealthCap. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1R inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumours. #lifesciences #biopharma #oncology #investment https://lnkd.in/dHrb-uMN
-
-
Bioqube Ventures is pleased to welcome SynOx Therapeutics to its portfolio, co-leading a $75M Series B alongside existing investors Forbion and HealthCap. The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1R inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumours. #lifesciences #biopharma #oncology #investment https://lnkd.in/dHrb-uMN
-
-
Congratulations to the Bicara MT! Well done! Very (well) oversubscribed round. Happy to be part of this exciting journey.
Today, we are thrilled to announce the completion of our oversubscribed $165M Series C financing with support from new and existing leading healthcare investors, who share in Bicara’s vision for our lead clinical program, BCA101, to make a meaningful difference for patients. Following our Phase 1/1b data presentations at key medical meetings in 2023, momentum at Bicara is greater than ever and this financing is a testament to our progress as we work to provide first-in-class therapies to patients with #headandneckcancer. We also are excited to welcome Carolyn Ng, Ph.D., to our board of directors. Her shared commitment to our mission will play a pivotal role in our growth and development. Read more in the release here: https://lnkd.in/ey_zX4FA
-
Excited to announce that Odile Rundquist and Janine Schuurman have joined us as Advisors. With 15+ years in the healthcare market as a sell-side Pharma analyst and scientific advisor to a large Swiss family office, Odile’s expertise is a great addition to the Bioqube’s team. Looking ahead to 2024, we anticipate Odile taking on a more significant role, aligning with our fundraising strategy. Until recently, Janine served as the Senior Vice President Antibody Research and Technologies at Genmab. Her 20+ years of antibody research and development expertise brings a wealth of insights, knowledge and deep scientific brain power to our group. Stay tuned for future updates!
-
-
Exciting update from our portfolio company @Bicara Therapeutics at @ESMO !
Yesterday, our Chief Medical Officer David Raben, M.D., and team presented updated interim data from our ongoing Phase 1/1b study of BCA101, our first-in-class bifunctional EGFR/TGF-β antibody, in those with HPV-negative recurrent/metastatic head and neck squamous cell carcinoma at the European Society for Medical Oncology's #ESMO23 Congress. Read more in the release below.
-
Fellowship opportunity! Do you have a scientific background, are you passionate about developing therapeutics and eager to learn more about what makes venture capital tick in biotech? Then this 6-month Fellowship program at Bioqube might be the right fit for you! Find out more in the description below ⤵️ #vc #biotech #fellowship
-
Welcome Krishna Polu ! What a great addition to our Bioqube Ventures team! Proud to be part of this family!
-